Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic players
- PMID: 39917316
- PMCID: PMC11799969
- DOI: 10.1016/j.jtauto.2025.100272
Autoantibodies in systemic sclerosis: From disease bystanders to pathogenic players
Abstract
Autoantibodies (Aab) are recognized as key indicators in the diagnosis, classification, and monitoring of systemic autoimmune diseases (AID). Recent studies have expanded knowledge through the discovery of new antigenic targets, advanced methods for measuring Aab levels, and understanding their possible pathogenic roles in AID. This narrative review uses systemic sclerosis (SSc) as an example to highlight the importance of Aab associated with HEp-2 immunofluorescence assay positivity (traditionally referred as antinuclear antibodies [ANA]), exploring recent developments in the field. Firstly, we outline the various types of ANA found in SSc and their links with specific disease features. Newly discovered antibodies shed light on SSc cases where Aab had previously gone unidentified. Secondly, we emphasize the necessity for novel quantitative techniques to track Aab levels over time by gathering data regarding the timing of Aab occurrence relative to SSc symptoms and the relationships between Aab concentrations and disease severity. Finally, we discuss the experimental findings suggesting a potential direct role of Aab in the development of SSc. The advancements surrounding Aab provide insights into new disease mechanisms and may lead to innovative diagnostic and treatment approaches.
Keywords: Antinuclear antibodies; Autoantibodies; Pathogenic autoantibodies; Systemic sclerosis.
© 2025 Published by Elsevier B.V.
Conflict of interest statement
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Aurélien Chepy reports travel reimbursement from Vitalair, outside the submitted work. David Launay reports consulting and speaking fees from Takeda Pharmaceutical Company Limited, CSL Behring LLC, Biocryst Pharmaceuticals, Inc; outside the submitted work. David Launay reports funding grants with CSL Behring LLC and Octapharma AG, outside the submitted work. Vincent Sobanski reports consulting and speaking fees from Boehringer Ingelheim, Fresenius Kabi France LLC, Grifols Inc and Ultragenyx; and research support from CSL Behring, Grifols; outside the submitted work. The other authors declare no conflicts of interest.
Figures
References
-
- LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., Rowell N., Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 1988;15:202–205. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
